You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the CYTALUX (pafolacianine sodium) Drug Profile, 2024 PDF Report in the Report Store ~

CYTALUX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cytalux patents expire, and what generic alternatives are available?

Cytalux is a drug marketed by On Target Labs and is included in one NDA. There are six patents protecting this drug.

This drug has thirty-five patent family members in twelve countries.

The generic ingredient in CYTALUX is pafolacianine sodium. One supplier is listed for this compound. Additional details are available on the pafolacianine sodium profile page.

DrugPatentWatch® Generic Entry Outlook for Cytalux

Cytalux will be eligible for patent challenges on November 29, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 26, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CYTALUX?
  • What are the global sales for CYTALUX?
  • What is Average Wholesale Price for CYTALUX?
Summary for CYTALUX
International Patents:35
US Patents:6
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
What excipients (inactive ingredients) are in CYTALUX?CYTALUX excipients list
DailyMed Link:CYTALUX at DailyMed
Drug patent expirations by year for CYTALUX
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CYTALUX
Generic Entry Date for CYTALUX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for CYTALUX

US Patents and Regulatory Information for CYTALUX

CYTALUX is protected by six US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CYTALUX is ⤷  Subscribe.

This potential generic entry date is based on patent 9,341,629.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,333,270 ⤷  Subscribe Y Y ⤷  Subscribe
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,789,208 ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CYTALUX

When does loss-of-exclusivity occur for CYTALUX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13381391
Patent: Fluorescence imaging of inflammatory diseases
Estimated Expiration: ⤷  Subscribe

Patent: 13383382
Patent: Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Estimated Expiration: ⤷  Subscribe

Patent: 13383386
Patent: Methods of manufacture and synthesis of amino acid linking groups conjugated to compounds used for targeted imaging of tumors
Estimated Expiration: ⤷  Subscribe

Patent: 17203340
Patent: Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 2015022810
Patent: síntese e composição de grupos de ligação de aminoácidos conjugados a compostos utilizados para a criação de imagens específicas de tumores
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 02205
Patent: IMAGERIE PAR FLUORESCENCE DE MALADIES INFLAMMATOIRES (FLUORESCENCE IMAGING OF INFLAMMATORY DISEASES)
Estimated Expiration: ⤷  Subscribe

Patent: 03727
Patent: PROCEDES DE FABRICATION ET DE SYNTHESE DE GROUPES DE LIAISON D'ACIDE AMINE CONJUGUES A DES COMPOSES UTILISES POUR L'IMAGERIE CIBLEE DE TUMEURS (METHODS OF MANUFACTURE AND SYNTHESIS OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR TARGETED IMAGING OF TUMORS)
Estimated Expiration: ⤷  Subscribe

Patent: 03994
Patent: SYNTHESE ET COMPOSITION DE GROUPES DE LIAISON D'ACIDES AMINES CONJUGUES A DES COMPOSES UTILISES POUR L'IMAGERIE CIBLEE DE TUMEURS (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS)
Estimated Expiration: ⤷  Subscribe

China

Patent: 5120903
Patent: Methods of manufacture and synthesis of amino acid linking groups conjugated to compounds used for targeted imaging of tumors
Estimated Expiration: ⤷  Subscribe

Patent: 5228628
Patent: Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Estimated Expiration: ⤷  Subscribe

Patent: 5492905
Patent: Fluorescence imaging of inflammatory diseases
Estimated Expiration: ⤷  Subscribe

Eurasian Patent Organization

Patent: 9738
Patent: СИНТЕЗ И КОМПОЗИЦИЯ АМИНОКИСЛОТНЫХ ЛИНКЕРНЫХ ГРУПП, КОНЪЮГИРОВАННЫХ С СОЕДИНЕНИЯМИ, ПРИМЕНЯЕМЫМИ ДЛЯ НАПРАВЛЕННОЙ ВИЗУАЛИЗАЦИИ ОПУХОЛЕЙ (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS)
Estimated Expiration: ⤷  Subscribe

Patent: 1591802
Patent: СИНТЕЗ И КОМПОЗИЦИЯ АМИНОКИСЛОТНЫХ ЛИНКЕРНЫХ ГРУПП, КОНЪЮГИРОВАННЫХ С СОЕДИНЕНИЯМИ, ПРИМЕНЯЕМЫМИ ДЛЯ НАПРАВЛЕННОЙ ВИЗУАЛИЗАЦИИ ОПУХОЛЕЙ
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 68335
Patent: SYNTHÈSE ET COMPOSITION DE GROUPES DE LIAISON D'ACIDES AMINÉS CONJUGUÉS À DES COMPOSÉS UTILISÉS POUR L'IMAGERIE CIBLÉE DE TUMEURS (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS)
Estimated Expiration: ⤷  Subscribe

Patent: 68614
Patent: PROCÉDÉS DE FABRICATION ET DE SYNTHÈSE DE GROUPES DE LIAISON D'ACIDE AMINÉ CONJUGUÉS À DES COMPOSÉS UTILISÉS POUR L'IMAGERIE CIBLÉE DE TUMEURS (METHODS OF MANUFACTURE AND SYNTHESIS OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR TARGETED IMAGING OF TUMORS)
Estimated Expiration: ⤷  Subscribe

Patent: 72320
Patent: IMAGERIE PAR FLUORESCENCE DE MALADIES INFLAMMATOIRES (METHODS OF IMAGING INFLAMMATORY DISEASES BY LIGANDS CONJUGATED TO FLUORESCENT COMPOUNDS)
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 18257
Patent: 用於使腫瘤靶向成像的化合物綴合的氨基酸連接基的製備和合成方法 (METHODS OF MANUFACTURE AND SYNTHESIS OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR TARGETED IMAGING OF TUMORS)
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 0509
Patent: דימות פלואורסנטי של מחלות דלקתיות (Fluorescence imaging of inflammatory diseases)
Estimated Expiration: ⤷  Subscribe

Patent: 0673
Patent: סינתזה והרכב של קבוצות קושרות חומצות אמינו מצומדות לתרכובות המשמשות להדמיה ממוקדת של גידולים (Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors)
Estimated Expiration: ⤷  Subscribe

Patent: 0828
Patent: שיטות לייצור וסינתזה של קבוצות קושרות חומצת אמינו מצומדות לתרכובות המשמשות להדמיה ממוקדת של גידולים (Methods of manufacture and synthesis of amino acid linking groups conjugated to compounds used for targeted imaging of tumors)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 92799
Estimated Expiration: ⤷  Subscribe

Patent: 70981
Estimated Expiration: ⤷  Subscribe

Patent: 16512240
Patent: 蛍光性化合物とコンジュゲートさせたリガンドによる炎症性疾患の蛍光イメージング
Estimated Expiration: ⤷  Subscribe

Patent: 16512813
Patent: 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物
Estimated Expiration: ⤷  Subscribe

Patent: 16512814
Patent: 腫瘍の標的型画像化のために用いられる化合物にコンジュゲートされたアミノ酸連結基の製造および合成の方法
Estimated Expiration: ⤷  Subscribe

Patent: 17149776
Patent: 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物 (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUP CONJUGATED TO COMPOUND USED FOR THE TARGETED IMAGING OF TUMOR)
Estimated Expiration: ⤷  Subscribe

Patent: 17214425
Patent: 蛍光性化合物とコンジュゲートさせたリガンドによる炎症性疾患の蛍光イメージング (SYNTHESIS AND COMPOSITION OF AMINO ACID-LINKING GROUP CONJUGATED TO COMPOUND USED FOR TARGETED IMAGING OF TUMOR)
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 8184
Patent: SINTESIS Y COMPOSICION DE GRUPOS DE ENLACE DE AMINOACIDOS CONJUGADOS CON COMPUESTOS USADOS PARA LA TOMA DE IMAGENES DIRIGIDA DE TUMORES. (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS.)
Estimated Expiration: ⤷  Subscribe

Patent: 15011830
Patent: METODOS DE FABRICACION Y SINTESIS DE GRUPOS DE ENLACE DE AMINOACIDOS CONJUGADOS CON COMPUESTOS USADOS PARA LA OBTENCION DE IMAGENES DIRIGIDA DE LOS TUMORES. (METHODS OF MANUFACTURE AND SYNTHESIS OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR TARGETED IMAGING OF TUMORS.)
Estimated Expiration: ⤷  Subscribe

Patent: 15013219
Patent: IMAGENOLOGIA POR FLUORESCENCIA DE ENFERMEDADES INFLAMATORIAS. (FLUORESCENCE IMAGING OF INFLAMMATORY DISEASES.)
Estimated Expiration: ⤷  Subscribe

Patent: 15013223
Patent: SINTESIS Y COMPOSICION DE GRUPOS DE ENLACE DE AMINOACIDOS CONJUGADOS CON COMPUESTOS USADOS PARA LA TOMA DE IMAGENES DIRIGIDA DE TUMORES. (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS.)
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 65896
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CYTALUX around the world.

Country Patent Number Title Estimated Expiration
Eurasian Patent Organization 029738 СИНТЕЗ И КОМПОЗИЦИЯ АМИНОКИСЛОТНЫХ ЛИНКЕРНЫХ ГРУПП, КОНЪЮГИРОВАННЫХ С СОЕДИНЕНИЯМИ, ПРИМЕНЯЕМЫМИ ДЛЯ НАПРАВЛЕННОЙ ВИЗУАЛИЗАЦИИ ОПУХОЛЕЙ (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS) ⤷  Subscribe
Israel 240673 סינתזה והרכב של קבוצות קושרות חומצות אמינו מצומדות לתרכובות המשמשות להדמיה ממוקדת של גידולים (Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors) ⤷  Subscribe
China 105120903 Methods of manufacture and synthesis of amino acid linking groups conjugated to compounds used for targeted imaging of tumors ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

CYTALUX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for CYTALUX

Introduction to CYTALUX

CYTALUX, developed by On Target Laboratories, is a groundbreaking molecular imaging agent that illuminates lung and ovarian cancer during surgery, enabling surgeons to detect and remove cancerous tissue more effectively. Here, we delve into the market dynamics and financial trajectory of this innovative drug.

FDA Approval and Regulatory Milestones

CYTALUX received FDA approval for ovarian cancer in November 2021 and a supplemental approval for lung cancer in December 2022. These approvals were crucial in establishing the drug's legitimacy and paving the way for its commercialization[1][4].

Funding and Investment

On Target Laboratories secured a significant $30 million Series C financing round in November 2023, backed by prominent investors such as H.I.G. Capital, The Hurvis Group, Johnson & Johnson Innovation – JJDC, Inc., and others. This funding is critical for accelerating the commercial launch and expanding the market presence of CYTALUX[1][5].

Commercialization and Market Expansion

The recent funding will enable On Target Laboratories to expedite the commercial launch of CYTALUX, making it more accessible to patients and healthcare providers across the United States. The company aims to amplify its market presence, leveraging the support from both private equity and strategic investors[1].

Reimbursement and Access

In August 2023, the Centers for Medicare & Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for CYTALUX use in ovarian and lung cancer surgery. This NTAP allows CMS to provide hospitals with additional payment of up to 65% of the average cost of CYTALUX, significantly expanding access to the technology[1].

Technological Integration

The commercialization of CYTALUX is further enhanced by its compatibility with advanced surgical equipment. For instance, Stryker's 1788 Platform, the only minimally invasive surgical camera cleared for use with CYTALUX, was recently introduced. This convergence of financing, reimbursement, and technological integration creates a unique opportunity for On Target to expedite the expansion of CYTALUX[1].

Clinical Impact and Outcomes

CYTALUX has demonstrated impressive clinical outcomes in trials. Surgeons have reported the ability to see the borders of tumors in real time, allowing for more precise removal of cancerous tissue while preserving unaffected organ tissue. This has led to the removal of cancers that would have been missed without CYTALUX, as they were not visible on scans[4].

Market Reception and Adoption

The market reception of CYTALUX has been positive, with surgeons and healthcare providers recognizing its value in improving surgical outcomes. The drug's ability to illuminate even the tiniest tumors has been hailed as a game-changer in surgical imaging. This positive reception is expected to drive adoption and increase market share[1][4].

Financial Performance and Projections

While specific financial projections for CYTALUX are not detailed, the significant investment and reimbursement support indicate a strong financial trajectory. The $30 million Series C financing and the NTAP from CMS are expected to contribute substantially to the company's revenue growth. Additionally, the commercial launch in September 2023 marked the beginning of a new phase in generating revenue from CYTALUX sales[1][5].

Competitive Landscape

In the field of cancer imaging and treatment, CYTALUX stands out due to its unique ability to illuminate cancerous tissue during surgery. However, it operates in a competitive landscape where other biotechnology companies are also advancing innovative cancer treatments. For example, companies like CatalYm and ImmunoGen are developing novel therapies targeting different aspects of cancer treatment, but CYTALUX's specific application in surgical imaging sets it apart[2][3].

Strategic Partnerships and Collaborations

On Target Laboratories has benefited from strategic partnerships and collaborations, including participation in the NCI-sponsored SBIR Investor Initiatives. These initiatives helped the company secure additional funding and support from investors and strategic partners, further solidifying its position in the market[4].

Future Outlook

The future outlook for CYTALUX is promising, driven by its clinical efficacy, regulatory approvals, and strong financial backing. As the company continues to expand its market presence and integrate its technology with advanced surgical tools, it is poised to become a leading solution in intraoperative molecular imaging.

"The ability of CYTALUX to illuminate lung and ovarian cancer during surgery is a stellar example of what we describe at Olympus as 'making the invisible visible'" - Nacho Abia, Chief Strategy Officer at Olympus[1].

Key Takeaways

  • FDA Approvals: CYTALUX received FDA approvals for ovarian and lung cancer, marking significant regulatory milestones.
  • Funding: Secured $30 million Series C financing to accelerate commercialization.
  • Reimbursement: CMS granted NTAP, expanding access to the technology.
  • Technological Integration: Compatible with advanced surgical equipment like Stryker's 1788 Platform.
  • Clinical Impact: Demonstrated ability to improve surgical outcomes by illuminating cancerous tissue.
  • Market Reception: Positive reception from surgeons and healthcare providers.
  • Financial Trajectory: Strong financial outlook driven by investment and reimbursement support.

FAQs

What is CYTALUX used for?

CYTALUX is a molecular imaging agent used to illuminate lung and ovarian cancer during surgery, helping surgeons detect and remove cancerous tissue more effectively.

When did CYTALUX receive FDA approval?

CYTALUX received FDA approval for ovarian cancer in November 2021 and a supplemental approval for lung cancer in December 2022.

How is CYTALUX administered?

CYTALUX is administered via a single dose intravenous infusion prior to surgery.

What is the significance of the NTAP for CYTALUX?

The NTAP granted by CMS allows hospitals to receive additional payment of up to 65% of the average cost of CYTALUX, expanding access to the technology.

What is the role of strategic partnerships in CYTALUX's development?

Strategic partnerships, such as those facilitated by the NCI-sponsored SBIR Investor Initiatives, have been crucial in securing funding and support for the development and commercialization of CYTALUX.

Sources

  1. On Target Laboratories Secures $30 Million for Commercialization of CYTALUX (pafolacianine) Injection - PR Newswire
  2. CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab - Brandon BioCatalyst
  3. ImmunoGen is now part of AbbVie - ImmunoGen Investor Relations
  4. Lighting the Way to Detect Tumors During Surgery - National Cancer Institute
  5. On Target Laboratories Secures $30 Million for Commercialization of CYTALUX (pafolacianine) Injection - Johnson & Johnson Innovation

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.